Analysts Set Repligen Co. (NASDAQ:RGEN) PT at $190.25

Shares of Repligen Co. (NASDAQ:RGEN) have been given a consensus rating of “Moderate Buy” by the eleven research firms that are currently covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $190.25.

RGEN has been the topic of a number of research reports. StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a research note on Friday. Wells Fargo & Company initiated coverage on Repligen in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price objective on the stock. UBS Group reduced their price objective on Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a research note on Wednesday, July 31st. Stephens reissued an “overweight” rating and set a $170.00 target price on shares of Repligen in a research report on Tuesday, July 30th. Finally, JPMorgan Chase & Co. boosted their target price on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Wednesday, July 31st.

Repligen Stock Up 2.4 %

NASDAQ RGEN opened at $146.06 on Friday. The stock’s 50 day moving average is $140.26 and its 200 day moving average is $143.12. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen has a 12 month low of $113.50 and a 12 month high of $211.13. The stock has a market cap of $8.18 billion, a PE ratio of -394.59, a P/E/G ratio of 4.29 and a beta of 0.96.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The business had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. During the same quarter in the previous year, the company posted $0.23 EPS. The company’s revenue was up 9.7% compared to the same quarter last year. Research analysts predict that Repligen will post 1.52 EPS for the current fiscal year.

Insider Buying and Selling at Repligen

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the sale, the director now directly owns 139,840 shares in the company, valued at approximately $20,328,540.80. This represents a 13.70 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Repligen

Several hedge funds have recently made changes to their positions in RGEN. Andra AP fonden purchased a new stake in shares of Repligen during the 2nd quarter worth $25,000. International Assets Investment Management LLC purchased a new stake in shares of Repligen during the 2nd quarter worth $33,000. UMB Bank n.a. lifted its stake in shares of Repligen by 138.3% during the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 130 shares during the last quarter. Lazard Asset Management LLC lifted its stake in shares of Repligen by 206.1% during the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 136 shares during the last quarter. Finally, Blue Trust Inc. lifted its stake in shares of Repligen by 113.4% during the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 127 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.